Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1992 Feb;75(2):372–377.

Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells.

N Tandon 1, B P Morgan 1, A P Weetman 1
PMCID: PMC1384722  PMID: 1372592

Abstract

Human thyroid cells are resistant to lysis by the homologous membrane attack complex. By immunohistochemical staining we here show that normal thyroid cells and those in Graves' disease and Hashimoto's thyroiditis express two membrane attack complex-inhibiting proteins, CD59 antigen and membrane attack complex-inhibiting protein/homologous restriction factor (MIP/HRF). In vitro, the expression of both molecules was enhanced by interleukin-1 (IL-1), tumour necrosis factor (TNF) and interferon-gamma (IFN-gamma) and cytokine-treated thyroid cells were more resistant to lysis by homologous complement. Blocking experiments with monoclonal antibodies against CD59 antigen and MIP/HRF showed that both molecules contributed but CD59 antigen was the more important in mediating resistance to complement attack. Expression of these proteins may be an important determinant of the severity of tissue injury produced by complement-fixing thyroid peroxidase antibodies in autoimmune thyroid disease.

Full text

PDF
373

Images in this article

374Figure 1
on p.374
375Figure 3
on p.375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hideshima T., Okada N., Okada H. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology. 1990 Mar;69(3):396–401. [PMC free article] [PubMed] [Google Scholar]
  3. Holguin M. H., Fredrick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989 Jul;84(1):7–17. doi: 10.1172/JCI114172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hänsch G. M. The homologous species restriction of the complement attack: structure and function of the C8 binding protein. Curr Top Microbiol Immunol. 1989;140:109–118. doi: 10.1007/978-3-642-73911-8_9. [DOI] [PubMed] [Google Scholar]
  5. Kalderon A. E., Bogaars H. A. Immune complex deposits in Graves' disease and Hashimoto's thyroiditis. Am J Med. 1977 Nov;63(5):729–734. doi: 10.1016/0002-9343(77)90159-0. [DOI] [PubMed] [Google Scholar]
  6. Khoury E. L., Bottazzo G. F., Roitt I. M. The thyroid "microsomal" antibody revisited. Its paradoxical binding in vivo to the apical surface of the follicular epithelium. J Exp Med. 1984 Feb 1;159(2):577–591. doi: 10.1084/jem.159.2.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Khoury E. L., Hammond L., Bottazzo G. F., Doniach D. Presence of the organ-specific 'microsomal' autoantigen on the surface of human thyroid cells in culture: its involvement in complement-mediated cytotoxicity. Clin Exp Immunol. 1981 Aug;45(2):316–328. [PMC free article] [PubMed] [Google Scholar]
  8. Margolick J. B., Weetman A. P., Burman K. D. Immunohistochemical analysis of intrathyroidal lymphocytes in Graves' disease: evidence of activated T cells and production of interferon-gamma. Clin Immunol Immunopathol. 1988 May;47(2):208–218. doi: 10.1016/0090-1229(88)90073-6. [DOI] [PubMed] [Google Scholar]
  9. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  10. Miyazaki A., Hanafusa T., Itoh N., Miyagawa J., Kono N., Tarui S., Kiyotaki C., Yoshizaki K. Demonstration of interleukin-1 beta on perifollicular endothelial cells in the thyroid glands of patients with Graves' disease. J Clin Endocrinol Metab. 1989 Oct;69(4):738–744. doi: 10.1210/jcem-69-4-738. [DOI] [PubMed] [Google Scholar]
  11. Morgan B. P., Daw R. A., Siddle K., Luzio J. P., Campbell A. K. Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods. 1983 Nov 25;64(3):269–281. doi: 10.1016/0022-1759(83)90434-9. [DOI] [PubMed] [Google Scholar]
  12. Nose M., Katoh M., Okada N., Kyogoku M., Okada H. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology. 1990 Jun;70(2):145–149. [PMC free article] [PubMed] [Google Scholar]
  13. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  14. Roitt I. M., Pujol-Borrell R., Hanafusa T., Delves P. J., Bottazzo G. F., Kohn L. D. Asialoagalactothyroglobulin binds to the surface of human thyroid cells at a site distinct from the 'microsomal' autoantigen. Clin Exp Immunol. 1984 Apr;56(1):129–134. [PMC free article] [PubMed] [Google Scholar]
  15. Rollins S. A., Sims P. J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1;144(9):3478–3483. [PubMed] [Google Scholar]
  16. Rooney I. A., Morgan B. P. Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins. Immunology. 1990 Nov;71(3):308–311. [PMC free article] [PubMed] [Google Scholar]
  17. Schönermark S., Rauterberg E. W., Shin M. L., Löke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol. 1986 Mar 1;136(5):1772–1776. [PubMed] [Google Scholar]
  18. Sims P. J., Rollins S. A., Wiedmer T. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem. 1989 Nov 15;264(32):19228–19235. [PubMed] [Google Scholar]
  19. Todd I., Pujol-Borrell R., Hammond L. J., Bottazzo G. F., Feldmann M. Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol. 1985 Aug;61(2):265–273. [PMC free article] [PubMed] [Google Scholar]
  20. Turner M., Londei M., Feldmann M. Human T cells from autoimmune and normal individuals can produce tumor necrosis factor. Eur J Immunol. 1987 Dec;17(12):1807–1814. doi: 10.1002/eji.1830171220. [DOI] [PubMed] [Google Scholar]
  21. Watts M. J., Dankert J. R., Morgan E. P. Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids. Biochem J. 1990 Jan 15;265(2):471–477. doi: 10.1042/bj2650471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weetman A. P., Cohen S. B., Oleesky D. A., Morgan B. P. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol. 1989 Jul;77(1):25–30. [PMC free article] [PubMed] [Google Scholar]
  23. Weetman A. P., Freeman M., Borysiewicz L. K., Makgoba M. W. Functional analysis of intercellular adhesion molecule-1-expressing human thyroid cells. Eur J Immunol. 1990 Feb;20(2):271–275. doi: 10.1002/eji.1830200207. [DOI] [PubMed] [Google Scholar]
  24. Weetman A. P., Freeman M., Morgan B. P. Thyroid follicular cell function after non-lethal complement membrane attack. Clin Exp Immunol. 1990 Oct;82(1):69–74. doi: 10.1111/j.1365-2249.1990.tb05405.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Weetman A. P., McGregor A. M. Autoimmune thyroid disease: developments in our understanding. Endocr Rev. 1984 Spring;5(2):309–355. doi: 10.1210/edrv-5-2-309. [DOI] [PubMed] [Google Scholar]
  26. Weetman A. P., Volkman D. J., Burman K. D., Gerrard T. L., Fauci A. S. The in vitro regulation of human thyrocyte HLA-DR antigen expression. J Clin Endocrinol Metab. 1985 Nov;61(5):817–824. doi: 10.1210/jcem-61-5-817. [DOI] [PubMed] [Google Scholar]
  27. Wood L. C., Ingbar S. H. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. J Clin Invest. 1979 Nov;64(5):1429–1436. doi: 10.1172/JCI109601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zalman L. S., Wood L. M., Müller-Eberhard H. J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975–6979. doi: 10.1073/pnas.83.18.6975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES